Clinical Trial Search

Primary: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 — -1.62; -1.74; -1.95 episodes per 24 hours — p=<0.0001

Primary: Change From Baseline of the Average Pain Intensity Overall in the 12-week Maintenance Period of the Daily Pain Intensity on an 11-point Numeric Rating Scale (NRS)…

Primary: Overall Percentage of Patients With Adverse Events — 23.6; 71.2; 57.0 Percentage of Participants

Primary: Beta-cell Function After 52 Weeks of Therapy — 2.89; 1.15 ratio — p=0.0001

Primary: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum — 4.62; 4.03; -2.24; 5.60 Percentage change in BMD

Primary: Time From Randomization to Virologic Failure — 36; 24; 24; 24 Weeks

Primary: Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE) — 1; 1; 5; 25 Subjects

Primary: Summary of Adverse Events — 114; 21; 7; 17 participants

Primary: Change From Baseline MTE08 to MTE09 Endpoint in Draize Score — 0.0 units on a scale

Primary: Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120 — 84.1 percentage of participants — p=<0.001

Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…

Primary: Investigator Hemostatic Efficacy Assessment of Participants After 8 Hours Post Infusion — 1.70 Units on a scale

Primary: Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12 — 15.5; 16.0; 7.3; 3.3 units on a scale — p=<0.001

Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)

Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants